Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06675695 · ClinicalTrials.gov registry record
Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 4,864
- Enrollment target
NCT06675695: Completed study, sponsored by Brigham and Women's Hospital.
NCT06675695 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 4,864 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06675695 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 4,864 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Hazard ratio (95% CI)
Interventions
- DRUG New use of osimertinib
- DRUG New use of erlotinib or gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,864 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2025-11-01 |
What the finished NCT06675695 record still lists
NCT06675695 is an observational study that tracks outcomes without assigning an intervention. Its 4,864 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which New use of osimertinib is the first listed.
NCT06675695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06675695 about?
NCT06675695 is a clinical study titled "Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT06675695?
This trial is currently completed. The enrollment target is 4,864 participants. The study started on 2024-10-30. Estimated completion is 2025-11-01.
What interventions are being tested in trial NCT06675695?
The interventions under investigation include: New use of osimertinib (DRUG), New use of erlotinib or gefitinib (DRUG).
Who is sponsoring clinical trial NCT06675695?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05252754 · 4,874 participants · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
- NCT05929976 · 4,900 participants
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
- NCT05485675 · 4,800 participants · NA
Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI